Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Caffeine for Neurodevelopment in Preterm Infants
NCT00809055Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of caffeine in apnea of prematurity (AOP) and traumatic brain injury (TBI) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: White Matter Microstructural Maturation at 12 weeks. Started Nov 2008; status: completed.
02
Drugs
caffeine
03
Conditions
apnea of prematurity (AOP)traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00809055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809055.